Silexion Therapeutics Corp SLXN
0.26
0.00
0.00%
as of 25 Sep
- Market cap
- $1.4M
- P/E
- 0.0×
Follow SLXN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Nov '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.41 | 0.64 | 2.27 | 0.08 | 1.17 | 0.43 | 0.29 | — |
Net Debt/EBITDA |
0.38 | (0.14) | 1.00 | 0.05 | 0.04 | 0.26 | 0.00 | — |
Debt/Assets |
21.73% | 103.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.60 | (0.74) | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.91 | 0.51 | 0.92 | 1.40 | 1.86 | 0.38 | (0.62) | — |
Capex/Depreciation |
(0.64) | (0.88) | 1.47 | — | — | — | 0.00 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| 1,718.90% | 204.96% | 74.55% | (90.02%) | 570.61% | (0.34%) | 0.00% | — | |
| (236.40%) | (405.05%) | (8.10%) | 0.50% | (1.31%) | (189.18%) | (504.25%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(305.12%) | 1,322.85% | (174.51%) | (49.78%) | (1,275.68%) | 115.24% | 101.87% | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | — | — | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | — | — | — | — |
Free Cash Flow per Share |
(81.41) | (2,004.29) | (6,375.71) | 326.56 | (586.33) | (83.33) | 0.00 | — |
Cash per Share |
45.25 | 290.95 | 6,600.00 | 23.88 | 16.21 | 57.44 | — | — |
Shareholders Equity per Share |
19.57 | (949.76) | 4,287.14 | (481.12) | (39.46) | (188.89) | — | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Book value per Share |
19.57 | (949.76) | 4,287.14 | (481.12) | (39.46) | (188.89) | — | — |
Free Cash Flow |
(10.83) | (8.42) | (4.46) | 0.82 | (1.41) | (0.07) | 0.12 | — |
Working Capital |
3.88 | (1.27) | 2.78 | (1.17) | 0.06 | (0.17) | (0.19) | — |
Capital Expenditures |
(0.01) | (0.02) | 0.07 | — | — | — | 0.00 | — |
Net Current Asset Value |
2.03 | (4.60) | 2.72 | (117.89) | (115.10) | (0.17) | (0.19) | — |
| Other line items | ||||||||
Quick Ratio |
2.18 | 0.35 | 2.10 | 0.05 | 0.11 | 0.17 | 0.00 | — |
Depreciation/Fixed assets |
0.56 | 0.83 | 0.92 | — | — | — | 0.00 | — |
Cash ROIC |
(106.43%) | (4,343.30%) | (60.07%) | (71.42%) | 2,521.86% | 63.40% | 0.00% | — |
Accounts Payable Turnover |
0.00 | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Operating CF per Share |
(81.35) | (1,999.05) | (6,470.00) | 326.56 | (586.33) | (83.33) | 0.00 | — |
Capex per Share |
(0.07) | (5.24) | 94.29 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
0.86 | 0.62 | — | — | — | — | — | — |
Average Assets |
5.04 | 4.06 | 61.03 | 116.10 | 57.77 | 0.10 | 0.04 | — |
Average Common Equity |
(0.69) | (8.02) | (6.63) | (0.65) | (0.13) | 57.37 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | — | — | 0.00 | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates